Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furosemide during HoLEP for same-day discharge
NCT05620784Phase 3Recruiting
- Sponsor
- Northwestern University
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of furosemide in benign prostatic hyperplasia (BPH), sponsored by Northwestern University. Started Mar 2023; status: recruiting.
02
Drugs
furosemide
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT05620784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620784.